Article Text

Download PDFPDF

1137 SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy
  1. Duong Nguyen1,
  2. Mohamed Hammad2,
  3. Rachael Mooney2,
  4. Forrest Neuharth1,
  5. Ashley Alamillo1,
  6. Ivelina Minev1,
  7. Israel Romero1,
  8. Stephanie Songco1,
  9. Emma Kedl1,
  10. Yunyi Kang1,
  11. Hoi Ngai2,
  12. Marisa McDonald2,
  13. Linda Flores2,
  14. Dae Kim2,
  15. Jacqueline Lara2,
  16. Thomas Herrmann3,
  17. Barbara Härtl3,
  18. Laura Edith3,
  19. Daniela Kleinholz3,
  20. Boris Minev1,
  21. Karen Aboody2 and
  22. Antonio Santidrian1
  1. 1Calidi Therapeutics, San Diego, CA, USA
  2. 2City of Hope, Duarte, CA, USA
  3. 3StemVAC, Bernried, Germany


Background The therapeutic potential of the oncolytic virotherapy is severely restricted by multiple innate and adaptive immune barriers. To overcome this obstacle, we utilized adipose-derived stem cells (AD-MSC) loaded with tumor selective CAL1 oncolytic vaccinia virus to generate a new therapeutic agent called SNV1 (SuperNova-1). Intratumoral injection of SNV1 inhibited drastically tumor growth of multiple human cancer xenograft models at significant low virus titers. In syngeneic immunocompetent models, SNV1 showed a robust tumor growth inhibition and immune cell recruitment of both the local injected tumors and distant non-injected tumors.

Methods SNV1 was tested for its ability to resist humoral immunity-mediated virus inactivation in cell culture. In tumor-bearing mouse models, tumor growth inhibition of multiple human xenografts and murine syngeneic was examined by using either single or three dose regimens. Additionally, in bilateral tumor-bearing mouse models, immune profiles at different time courses of both treated and untreated tumors as well as lymph nodes were analyzed by flow cytometry. Anti-viral and anti-tumor immunity was analyzed by ELISPOT.

Results Data showed that SNV1 was more resistant to rapid inactivation by humoral immune system as compared to naked CAL1 virus leading to a significant and robust improvement of oncolytic virus therapeutic efficacy in human melanoma (MeWo), head and neck (Fadu) and triple negative breast (MDA-MB-231) cancer cells. Furthermore, SNV1 significantly inhibited the growth of the tumors even at the very low dose of 1.5x103 cells containing 1.6x104 PFU. In a bilateral colon cancer tumor-bearing immunocompetent mouse model CT26, data showed both one (1) and three (3) administrations of SNV1 significantly inhibit tumor growth of injected tumors in comparison with the naked CAL1 virus or controls. However, significant systemic therapeutic efficacy was only achieved by three (3) but not one (1) intratumoral administrations of SNV1 suggesting multiple intratumoral administrations of SNV1 were required to induce robust systemic activation of the immune system. Furthermore, tumor infiltrating lymphocytes (TILs) from both treated and untreated tumors showed increased CD4 and CD8 T-cell infiltrations while suppressing frequency of Tregs. Early recruitment of innate populations was observed in tested models.

Conclusions The SNV1 stem cell-based platform protects and potentiates oncolytic vaccinia virus by circumventing humoral innate and adaptive immune barriers, resulting in enhanced anti-cancer effects in tumor-bearing mouse models. SNV1 provided instantly active viral particles for immediate infection in the injected tumors which help transforming tumor environment from “cold” to “hot” locally and systemically.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.